X
首页 > 人才队伍 > 业务骨干 > 海洋新药筛选与评价中心 > 吴丽娟

吴丽娟

吴丽娟 高级工程师
位:

海洋新药筛选与评价中心

个人简介:

现任青岛海洋生物医药研究院海洋药物筛选与评价创新中心研发工程师,作为研发骨干,主要进行疾病模型建立以及评价技术体系建立,并进行糖类创新药物开发。

研究方向:

1.代谢类疾病动物模型和评价技术体系建立

2.海洋糖类创新药物研发

3.保健品功效及安全性评价


代表性成果:

参与了1类新药BG136临床前药理药效研究,并已获取新药临床批件。

共发表论文12篇,其中,以第1作者身份发表SCI一区论文2篇,参与发表SCI一区论文4篇。


代表性论文:

1、Anti-HBV activity and mechanism of marine-derived polyguluronate sulfate (PGS) in vitro. Carbohydr Polym. 2016; 143: 139-148. (第1作者,SCI一区,IF10.723)

2、Antitumor effect of soluble β-glucan as an immune stimulant. Int J Biol Macromol. 2021; 179: 116-124. (第1作者,SCI一区,IF8.025)

3、Na2S2O4@Co-metal organic framework (ZIF-67) @glucose oxidase for 

biofilm-infecting wound healing with immune activation. Int J Biol Macromol. 2023; 226: 1533-1546. (第2作者,SCI一区,IF8.025)

4、Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther. 2022; 7(1): 287. (第3作者,SCI一区,IF38.104)

5、Image-Guided TME-Improving Nano-Platform for Ca2+ Signal Disturbance and Enhanced Tumor PDT. Adv Healthc Mater. 2021;10(19): e2100789. (第3作者,SCI一区,IF11.093)

6、Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists. European journal of medicinal chemistry. 2022; 227: 113923.(第4作者,SCI一区,IF7.088)

7、BH3 mimetics derived from Bim-BH3 domain core region show PTP1B inhibitory activity. Bioorg Med Chem Lett. 2019; 29 (2): 244-247. (第2作者,IF2.83)

8、Discovery of Novel PTP1B Inhibitors Derived from the BH3 Domain of Proapoptotic Bcl-2 Proteins with Antidiabetic Potency. ACS Med Chem Lett. 2021; 12(6): 1017-1023. Published 2021 May 19. (第3作者,IF4.34)

9、A NO/ROS/RNS cascaded-releasing nano-platform for gas/PDT/PTT/immunotherapy of tumors. Biomater Sci. 2021; 9(17): 5824-5840. (第3作者,IF6.84) 

10、Neoagaro-oligosaccharide monomers inhibit inflammation in LPS-stimulated macrophages through suppression of MAPK and NF-κB pathways. Scientific reports, 2017; 7, 44252. (第4作者,IF4.38)

11、Myricetin and M10, a myricetin-3-O-β-d-lactose sodium salt, modify composition of gut microbiota in mice with ulcerative colitis. Toxicology letters, 2021; 346, 7–15. (第5作者,IF4.37)

12、A β-1,3/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator. Carbohydr Polym. 2019; 222, 114993.(第7作者,IF9.38)

专利:

作为主要发明人共参与申请发明专利10个:第一发明人2个、PCT专利2个、国内专利8个,并获得3个发明专利授权。

1. 以PTP1B为靶点的新型模拟肽化合物及其制备方法和应用,ZL201811517551.X,张传亮,王树林,路晓,吴丽娟,2022年4月1日授权;

2. 据古罗糖醛酸硫酸酯在制备抗乙型肝炎病毒的药物中的应用,ZL201510623466.1,赵峡,王伟,吴丽娟,管华诗,于广利,李春霞,2018年7月6日授权;

3. 一类PTP1B多肽抑制剂及其制备方法和应用,ZL201711313716.7,张传亮,王树林,路晓,吴丽娟,柳晓春,蔡兵,管华诗,2022年7月26日授权

员工
入口
联系
我们